Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer. BJS 2018; 105: 1630-1638.
Published: 27th June 2018
Authors: B. J. Noordman, E. W. de Bekker‐Grob, P. P. L. O. Coene, E. van der Harst, S. M. Lagarde, J. Shapiro et al.
After neoadjuvant chemoradiotherapy (nCRT) plus surgery for oesophageal cancer, 29 per cent of patients have a pathologically complete response in the resection specimen. Active surveillance after nCRT (instead of standard oesophagectomy) may improve health‐related quality of life (HRQoL), but patients need to undergo frequent diagnostic tests and it is unknown whether survival is worse than that after standard oesophagectomy. Factors that influence patients' preferences, and trade‐offs that patients are willing to make in their choice between surgery and active surveillance were investigated here.
A prospective discrete‐choice experiment was conducted. Patients with oesophageal cancer completed questionnaires 4–6 weeks after nCRT, before surgery. Patients' preferences were quantified using scenarios based on five aspects: 5‐year overall survival, short‐term HRQoL, long‐term HRQoL, the risk that oesophagectomy is still necessary, and the frequency of clinical examinations using endoscopy and PET–CT. Panel latent class analysis was used.
Some 100 of 104 patients (96·2 per cent) responded. All aspects, except the frequency of clinical examinations, influenced patients' preferences. Five‐year overall survival, the chance that oesophagectomy is still necessary and long‐term HRQoL were the most important attributes. On average, based on calculation of the indifference point between standard surgery and active surveillance, patients were willing to trade off 16 per cent 5‐year overall survival to reduce the risk that oesophagectomy is necessary from 100 per cent (standard surgery) to 35 per cent (active surveillance).
Patients are willing to trade off substantial 5‐year survival to achieve a reduction in the risk that oesophagectomy is necessary.Full text
You may also be interested in
Authors: T. Mizuno, T. Ebata, Y. Yokoyama, T. Igami, J. Yamaguchi, S. Onoe et al.
Authors: C. Andolfi, P. M. Fisichella
Systematic review of management of incidental gallbladder cancer after cholecystectomy. BJS 2019; 106: 32-45.
Authors: K. Søreide, R. V. Guest, E. M. Harrison, T. J. Kendall, O. J. Garden, S. J. Wigmore et al.
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Authors: T. Hølmebakk, B. Bjerkehagen, I. Hompland, S. Stoldt, K. Boye
Notes: Tumour rupture is most important
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma. BJS 2019; 106: 255-262.
Authors: B.‐Y. Wang, S.‐C. Wu, H.‐C. Chen, W.‐H. Hung, C.‐H. Lin, C.‐L. Huang et al.
Notes: Surgery after chemoradiation indicated
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma. BJS 2019; 106: 55-58.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Impact of postoperative complications on outcomes after oesophagectomy for cancer. BJS 2019; 106: 111-119.
Authors: L. Goense, J. Meziani, J. P. Ruurda, R. van Hillegersberg
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. BJS 2019; 106: 181-189.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?
Multicentre cohort study of antihypertensive and lipid‐lowering therapy cessation after bariatric surgery. BJS 2019; 106: 286-295.
Authors: J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika, D. Nocca et al.
Notes: Better than controls
Overall survival before and after centralization of gastric cancer surgery in the Netherlands. BJS 2018; 105: 1807-1815.
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practice makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus. BJS 2018; 105: 1793-1798.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Population‐based cohort study of diabetes mellitus and mortality in gastric adenocarcinoma. BJS 2018; 105: 1799-1806.
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk